Chemotherapeutic developer Odonate Therapeutics Inc. extended the 2017 biopharma IPO window, offering 6.25 million common shares at $24 apiece to raise $150 million. Although shares priced at the low end of the company's proposed range, Odonate bumped up the size of the offering, originally set at 5.88 million shares. Trading as ODT on Nasdaq, shares of the San Diego-based company closed Thursday at $23.